Skip to main content
Top
Published in: Annals of Surgical Oncology 5/2015

01-05-2015 | Hepatobiliary Tumors

Is Complete Liver Resection Without Resection of Synchronous Lung Metastases Justified?

Authors: Yoshihiro Mise, MD, Scott Kopetz, MD, Reza J. Mehran, MD, Thomas A. Aloia, MD, Claudius Conrad, MD, Kristoffer W. Brudvik, MD, Melissa W. Taggart, MD, Jean-Nicolas Vauthey, MD

Published in: Annals of Surgical Oncology | Issue 5/2015

Login to get access

Abstract

Background

Advances in multidisciplinary care are changing the prognostic impact of colorectal lung metastases. Resection of colorectal liver metastases (CLM) may benefit patients with synchronous lung metastases even when lung metastases are not resected. The aim of this study was to investigate the survival of patients undergoing complete resection of CLM in the setting of unresected lung metastases.

Patients and Methods

We compared survival among 98 patients who underwent resection of CLM with unresected lung metastases, 64 who received only chemotherapy for limited colorectal liver and lung metastases, and 41 who underwent resection of both liver and lung metastases. Prognostic factors were investigated in the patients who underwent resection of CLM only.

Results

The 3-year/5-year overall survival (OS) rates of patients with CLM resection only (42.9 %/13.1 %) were better than those of patients treated with chemotherapy only (14.1 %/1.6 %; p < 0.01) but worse than those of patients with resection of liver and lung metastases (68.9 %/56.9 %; p < 0.01). Multivariate analysis of patients with CLM resection only revealed that KRAS mutation [hazard ratio (HR) 2.10; 95 % confidence interval (CI) 1.21–3.64; p < 0.01] and rectal primary tumor (HR 1.72; 95 % CI 1.02–2.88; p = 0.04) were independent predictors of worse OS. Survival of patients without these risk factors was similar to that of patients with curative metastasectomy.

Conclusions

Complete resection of metastases remains the primary goal of treatment for stage IV colorectal cancer. Resection of CLM without resection of lung metastases is associated with an intermediate survival between that of patients treated with palliative and curative intent and should be considered in selected patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol. 1998;16:301–8. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol. 1998;16:301–8.
2.
go back to reference Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–25.CrossRefPubMedCentralPubMed Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–25.CrossRefPubMedCentralPubMed
3.
go back to reference Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.CrossRefPubMedCentralPubMed Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.CrossRefPubMedCentralPubMed
4.
go back to reference Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–83.CrossRefPubMedCentralPubMed Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677–83.CrossRefPubMedCentralPubMed
5.
go back to reference Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715–22.CrossRefPubMedCentralPubMed Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005;241:715–22.CrossRefPubMedCentralPubMed
6.
go back to reference Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672–80.CrossRefPubMed Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27:672–80.CrossRefPubMed
7.
go back to reference Galandiuk S, Wieand HS, Moertel CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet. 1992;174:27–32.PubMed Galandiuk S, Wieand HS, Moertel CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet. 1992;174:27–32.PubMed
8.
go back to reference Maithel SK, Ginsberg MS, D’Amico F, et al. Natural history of patients with subcentimeter pulmonary nodules undergoing hepatic resection for metastatic colorectal cancer. J Am Coll Surg. 2010;210:31–8.CrossRefPubMed Maithel SK, Ginsberg MS, D’Amico F, et al. Natural history of patients with subcentimeter pulmonary nodules undergoing hepatic resection for metastatic colorectal cancer. J Am Coll Surg. 2010;210:31–8.CrossRefPubMed
9.
go back to reference Mitry E, Guiu B, Cosconea S, et al. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010;59:1383–8.CrossRefPubMed Mitry E, Guiu B, Cosconea S, et al. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010;59:1383–8.CrossRefPubMed
10.
go back to reference Kim CH, Huh JW, Kim HJ, et al. Factors influencing oncological outcomes in patients who develop pulmonary metastases after curative resection of colorectal cancer. Dis Colon Rectum. 2012;55:459–64.CrossRefPubMed Kim CH, Huh JW, Kim HJ, et al. Factors influencing oncological outcomes in patients who develop pulmonary metastases after curative resection of colorectal cancer. Dis Colon Rectum. 2012;55:459–64.CrossRefPubMed
11.
go back to reference Nordholm-Carstensen A, Krarup PM, Jorgensen LN, et al. Occurrence and survival of synchronous pulmonary metastases in colorectal cancer: a nationwide cohort study. Eur J Cancer. 2014;50:447–56.CrossRefPubMed Nordholm-Carstensen A, Krarup PM, Jorgensen LN, et al. Occurrence and survival of synchronous pulmonary metastases in colorectal cancer: a nationwide cohort study. Eur J Cancer. 2014;50:447–56.CrossRefPubMed
12.
go back to reference Gomez D, Morris-Stiff G, Toogood GJ, et al. Interaction of tumour biology and tumour burden in determining outcome after hepatic resection for colorectal metastases. HPB (Oxford). 2010;12:84–93.CrossRefPubMedCentralPubMed Gomez D, Morris-Stiff G, Toogood GJ, et al. Interaction of tumour biology and tumour burden in determining outcome after hepatic resection for colorectal metastases. HPB (Oxford). 2010;12:84–93.CrossRefPubMedCentralPubMed
13.
go back to reference Thomassen I, van Gestel YR, Lemmens VE, et al. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Dis Colon Rectum. 2013;56:1373–80.CrossRefPubMed Thomassen I, van Gestel YR, Lemmens VE, et al. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Dis Colon Rectum. 2013;56:1373–80.CrossRefPubMed
14.
go back to reference Hwang M, Jayakrishnan TT, Green DE, et al. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur J Cancer. 2014;50:1747–57.CrossRefPubMed Hwang M, Jayakrishnan TT, Green DE, et al. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur J Cancer. 2014;50:1747–57.CrossRefPubMed
15.
go back to reference Yoon YS, Kim CW, Lim SB, et al. Palliative surgery in patients with unresectable colorectal liver metastases: a propensity score matching analysis. J Surg Oncol. 2014;109:239–44.CrossRefPubMed Yoon YS, Kim CW, Lim SB, et al. Palliative surgery in patients with unresectable colorectal liver metastases: a propensity score matching analysis. J Surg Oncol. 2014;109:239–44.CrossRefPubMed
16.
go back to reference De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 1:753–62.CrossRef De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 1:753–62.CrossRef
17.
go back to reference Vauthey J-N, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619–27.CrossRefPubMed Vauthey J-N, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619–27.CrossRefPubMed
18.
go back to reference Cejas P, Lopez-Gomez M, Aguayo C, et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One. 2009;4:e8199.CrossRefPubMedCentralPubMed Cejas P, Lopez-Gomez M, Aguayo C, et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One. 2009;4:e8199.CrossRefPubMedCentralPubMed
19.
go back to reference Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17:1122–30.CrossRefPubMed Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17:1122–30.CrossRefPubMed
20.
go back to reference Brouquet A, Vauthey JN, Contreras CM, et al. Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: a study of 112 patients with limited lung metastatic disease. J Am Coll Surg. 2011;213:62–9.CrossRefPubMed Brouquet A, Vauthey JN, Contreras CM, et al. Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: a study of 112 patients with limited lung metastatic disease. J Am Coll Surg. 2011;213:62–9.CrossRefPubMed
21.
go back to reference Mise Y, Mehran RJ, Aloia TA, et al. Simultaneous lung resection via a transdiaphragmatic approach in patients undergoing liver resection for synchronous liver and lung metastases. Surgery. doi: 10.1016/j.surg.2014.04.050. Mise Y, Mehran RJ, Aloia TA, et al. Simultaneous lung resection via a transdiaphragmatic approach in patients undergoing liver resection for synchronous liver and lung metastases. Surgery. doi: 10.​1016/​j.​surg.​2014.​04.​050.
22.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedCentralPubMed Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedCentralPubMed
23.
go back to reference Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084–91.CrossRefPubMedCentralPubMed Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084–91.CrossRefPubMedCentralPubMed
24.
go back to reference Adams RB, Aloia TA, Loyer E, et al. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15:91–103.CrossRefPubMedCentralPubMed Adams RB, Aloia TA, Loyer E, et al. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15:91–103.CrossRefPubMedCentralPubMed
25.
go back to reference Kohne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13:308–17.CrossRefPubMed Kohne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13:308–17.CrossRefPubMed
26.
go back to reference Treasure T, Brew-Graves C, Fallowfield L, et al. The need to determine whether lung metastasectomy improves survival in advanced colorectal cancer. BMJ. 2014;348:g4085.CrossRefPubMed Treasure T, Brew-Graves C, Fallowfield L, et al. The need to determine whether lung metastasectomy improves survival in advanced colorectal cancer. BMJ. 2014;348:g4085.CrossRefPubMed
27.
go back to reference Fiorentino F, Treasure T. Pulmonary metastasectomy: are observational studies sufficient evidence for effectiveness? Ann Thorac Surg. 2013;96:1129–31.CrossRefPubMed Fiorentino F, Treasure T. Pulmonary metastasectomy: are observational studies sufficient evidence for effectiveness? Ann Thorac Surg. 2013;96:1129–31.CrossRefPubMed
28.
go back to reference Treasure T, Fallowfield L, Lees B, et al. Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial. Thorax. 2012;67:185–7.CrossRefPubMed Treasure T, Fallowfield L, Lees B, et al. Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial. Thorax. 2012;67:185–7.CrossRefPubMed
29.
go back to reference Treasure T, Fallowfield L, Lees B. Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial. J Thorac Oncol. 2010;5:S203–6.CrossRefPubMed Treasure T, Fallowfield L, Lees B. Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial. J Thorac Oncol. 2010;5:S203–6.CrossRefPubMed
30.
go back to reference Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29:1083–90.CrossRefPubMedCentralPubMed Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29:1083–90.CrossRefPubMedCentralPubMed
31.
go back to reference Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23:2619–26.CrossRefPubMedCentralPubMed Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23:2619–26.CrossRefPubMedCentralPubMed
32.
go back to reference Johnston FM, Kneuertz PJ, Pawlik TM Resection of non-hepatic colorectal cancer metastasis. J Gastrointest Oncol. 2012;3:59–68.PubMedCentralPubMed Johnston FM, Kneuertz PJ, Pawlik TM Resection of non-hepatic colorectal cancer metastasis. J Gastrointest Oncol. 2012;3:59–68.PubMedCentralPubMed
33.
go back to reference Quan D, Gallinger S, Nhan C, et al. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery. 2012;151:860–70.CrossRefPubMed Quan D, Gallinger S, Nhan C, et al. The role of liver resection for colorectal cancer metastases in an era of multimodality treatment: a systematic review. Surgery. 2012;151:860–70.CrossRefPubMed
34.
go back to reference Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011;104:1020–6.CrossRefPubMedCentralPubMed Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011;104:1020–6.CrossRefPubMedCentralPubMed
35.
go back to reference Iida T, Nomori H, Shiba M, et al. Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg. 2013;257:1059–64.CrossRefPubMed Iida T, Nomori H, Shiba M, et al. Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg. 2013;257:1059–64.CrossRefPubMed
36.
go back to reference Blackmon SH, Stephens EH, Correa AM, et al. Predictors of recurrent pulmonary metastases and survival after pulmonary metastasectomy for colorectal cancer. Ann Thorac Surg. 2012;94:1802–9.CrossRefPubMed Blackmon SH, Stephens EH, Correa AM, et al. Predictors of recurrent pulmonary metastases and survival after pulmonary metastasectomy for colorectal cancer. Ann Thorac Surg. 2012;94:1802–9.CrossRefPubMed
Metadata
Title
Is Complete Liver Resection Without Resection of Synchronous Lung Metastases Justified?
Authors
Yoshihiro Mise, MD
Scott Kopetz, MD
Reza J. Mehran, MD
Thomas A. Aloia, MD
Claudius Conrad, MD
Kristoffer W. Brudvik, MD
Melissa W. Taggart, MD
Jean-Nicolas Vauthey, MD
Publication date
01-05-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 5/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4207-3

Other articles of this Issue 5/2015

Annals of Surgical Oncology 5/2015 Go to the issue